|
Loading...
| ||||||||||||||
Recent Publications by Oxford BioMedica Ltd.: |  | |
| Factors that influence VSV-G pseudotyping and transduction efficiency of lentiviral vectors-in vitro and in vivo implications.
Pseudotyping viral vectors with vesicular stomatitis virus glycoprotein... | Oxford BioMedica Ltd., The Medawar Centre, Robert Robinson Avenue, Oxford | J Gene Med. 2007 May;9(5):345-56.
DOI Direct Link |
| Viral vectors for cancer immunotherapy.
Over the last decade, immunotherapy approaches for the treatment of cancer... | Oxford BioMedica Ltd., Oxford Science Park, Oxford, OX4 4GA, United | Front Biosci. 2006 Jan 1;11:804-17. |
| Silencing mutant SOD1 using RNAi protects against neurodegeneration and extends survival in an ALS model.
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease... | Oxford Biomedica Ltd, Medawar Centre, The Oxford Science Park, Oxford, OX4 | Nat Med. 2005 Apr;11(4):429-33. Epub 2005 Mar 13.
DOI Direct Link |
| Genetic amplification of the transcriptional response to hypoxia as a novel means of identifying regulators of angiogenesis.
The cellular response to hypoxia involves the promotion of angiogenesis,... | Biological Systems Group, Oxford BioMedica Ltd., OX4 4GA, Oxford, United | Genomics. 2004 Jan;83(1):1-8. |
| Identification of potential stroke targets by lentiviral vector mediated overexpression of HIF-1 alpha and HIF-2 alpha in a primary neuronal model of hypoxia.
The identification of genes differentially regulated by ischemia will lead... | Oxford Biomedica Ltd, UK. | J Cereb Blood Flow Metab. 2004 Feb;24(2):245-58.
DOI Direct Link |
Oxford BioMedica Ltd. Patents: |  |
| US Patent No. | Title |
| 5942434 | Nucleic acid constructs comprising hypoxia response elements |
| 6669936 | Retroviral vectors |
| 6783981 | Anti-viral vectors |
| 6800281 | Lentiviral-mediated growth factor gene therapy for neurodegenerative diseases |
| 6808922 | Retroviral vectors comprising a functional splice donor site and a functional splice acceptor site |